Short Interest in Biodesix, Inc. (NASDAQ:BDSX) Increases By 499.1%

Biodesix, Inc. (NASDAQ:BDSX) saw a significant growth in short interest in January. As of January 15th, there was short interest totaling 483,591 shares, a growth of 499.1% from the December 31st total of 80,722 shares. Based on an average trading volume of 7,865,756 shares, the short-interest ratio is presently 0.1 days. Currently, 8.7% of the company’s stock are sold short. Currently, 8.7% of the company’s stock are sold short. Based on an average trading volume of 7,865,756 shares, the short-interest ratio is presently 0.1 days.

Biodesix Price Performance

Shares of BDSX opened at $11.08 on Wednesday. The company’s 50-day moving average is $7.75 and its 200-day moving average is $7.73. The company has a debt-to-equity ratio of 41.11, a current ratio of 1.84 and a quick ratio of 1.84. The firm has a market capitalization of $88.15 million, a PE ratio of -1.99 and a beta of 0.60. Biodesix has a fifty-two week low of $3.44 and a fifty-two week high of $21.60.

Biodesix (NASDAQ:BDSX) last announced its quarterly earnings results on Monday, November 3rd. The company reported ($1.16) EPS for the quarter, beating analysts’ consensus estimates of ($1.60) by $0.44. The business had revenue of $21.77 million for the quarter, compared to analyst estimates of $20.98 million. Biodesix had a negative net margin of 49.31% and a negative return on equity of 504.41%. Equities analysts forecast that Biodesix will post -0.35 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on BDSX. Wall Street Zen raised shares of Biodesix from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Biodesix in a research report on Monday, December 22nd. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $32.50.

Insider Buying and Selling

In other news, Director Jack W. Schuler purchased 20,000 shares of the company’s stock in a transaction on Monday, January 26th. The shares were purchased at an average price of $11.80 per share, with a total value of $236,000.00. Following the purchase, the director directly owned 1,563,210 shares of the company’s stock, valued at $18,445,878. This trade represents a 1.30% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Over the last quarter, insiders have acquired 182,465 shares of company stock valued at $2,084,616 and have sold 2,247 shares valued at $18,154. Corporate insiders own 30.10% of the company’s stock.

Institutional Investors Weigh In On Biodesix

A number of institutional investors have recently modified their holdings of BDSX. Aberdeen Group plc bought a new position in shares of Biodesix during the fourth quarter worth approximately $1,784,000. XTX Topco Ltd grew its stake in shares of Biodesix by 99.4% during the second quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock worth $58,000 after buying an additional 102,494 shares during the last quarter. Oracle Investment Management Inc. acquired a new position in shares of Biodesix during the third quarter worth $113,000. Finally, Millennium Management LLC bought a new position in shares of Biodesix in the 3rd quarter valued at $113,000. Institutional investors own 20.96% of the company’s stock.

About Biodesix

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.